List view / Grid view
Antibiotics are a type of antimicrobial drug used in the treatment and prevention of bacterial infections.
3 June 2015 | By Victoria White
Auspherix has raised £6 million in a Series A venture financing and is establishing operations on the Stevenage Bioscience Catalyst site...
2 June 2015 | By Victoria White
MGB Biopharma has developed a stable IV formulation of MGB-BP-3 for the treatment of Gram-positive hospital-acquired infections...
21 May 2015 | By Victoria White
Researchers have developed a second-generation of spectinomycin that shows early effectiveness against common bacterial infections...
19 May 2015 | By Victoria White
Researchers have discovered a key cause of life threatening heart complications, conditions that frequently follow severe Streptococcus pneumoniae infection..
14 May 2015 | By Victoria White
Antibiotic Research UK has welcomed this latest report to come from Jim O’Neill's Review on Antimicrobial Resistance and has endorses its recommendations...
27 April 2015 | By Victoria White
Preclinical data from Synthetic Biologics’ novel SYN-005 programme for the treatment of Pertussis were presented in two posters at ECCMID 2015...
16 April 2015 | By Victoria White
Ferring and Institut Pasteur are collaborating aimed at identifying and developing bacteriophages to treat patients with inflammatory bowel disease (IDB)...
7 April 2015 | By Victoria White
Nabriva, a biotechnology company focused on developing pleuromutilins, has announced the successful completion of a $120 million Series B financing...
9 March 2015 | By Phico Therapeutics
Phico Therapeutics, a biotechnology company developing a novel platform technology for a new generation of antibiotics aimed at overcoming antibacterial resistance, has been awarded a £2.25M Translation Award by the Wellcome Trust to develop its SASPject™ PT4 antibiotic, aimed at Escherichia coli and Klebsiella pneumoniae...
3 February 2015 | By Motif Bio
Motif Bio plc is seeking to raise at least £4 million through a placing of new ordinary shares and admission to trading on AIM...
3 February 2015 | By Innovative Medicines Initiative (IMI)
Two years after the start of the Innovative Medicines Initiative (IMI)-funded New Drugs 4 Bad Bugs (ND4BB) programme, the first patient has been enrolled into a Phase 2 trial sponsored by MedImmune, the global biologics research and development arm of AstraZeneca. The trial with MEDI4893 is among mechanically ventilated intubated…
13 January 2015 | By Roche
Roche, Meiji Seika Pharma (Meiji) and Fedora announced that they have entered into a license agreement for the development and commercialization of OP0595, a beta-lactamase inhibitor in phase I clinical development...
19 November 2014 | By Diamond
Structure of EzrA protein could help identify new antibiotic targets...
15 October 2014 | By Domainex
Domainex Ltd. and Auspherix Pty Ltd announced a collaboration that will progress Auspherix’s novel anti-infective drug discovery programme towards the nomination of a clinical candidate...
